Gentian Diagnostics Secures Patent for Diagnostic Precision

Gentian Diagnostics ASA (DE:6FK) has released an update.

Gentian Diagnostics ASA has been granted a European patent for a novel reference method to improve accuracy in diagnostic assays, specifically for NT-proBNP concentration in blood samples. This mass spectrometry-based method will help harmonize NT-proBNP measurements, offering potential benefits to healthcare providers and patients. The company specializes in immunoassays and provides diagnostic reagents globally from its headquarters in Norway.

For further insights into DE:6FK stock, check out TipRanks’ Stock Analysis page.